CARBIROID Tablet

Indication:

For treatment of hyperthyroidism, including prior to surgery or radiotherapy; as well as concomitant therapy with radio­iodine treatment.

Dosage:

Adults: Oral, 30-60 mg daily in divided doses every 8 hours, the dosage being gradually reduced to the smallest effective dose, usually 5 to 20 mg daily.

Children: Oral, 2.5-10 mg every 8 hours, the dosage being reduced gradually according to the clinical response.

Note: The information given here is limited. For further information, consult your doctor or pharmacist.

Breast feeding should not be undertaken by lactating patients.

Skin rash, nausea, headache, gastrointestinal upsets, joint pains, agranulocytosis.

1. Concurrent use with anticoagulants and heparin is not recommended.

2. Concurrent use with agranulocytosis producing medications may increase the risk of agranulocytosis.

Carbimazole may cause white cell disorders such as neutropenia and agranulocytosis, which may be fatal if treatment with carbimazole is not stopped promptly. These reactions usually occur during the first 3 months of therapy. and in most cases, are reversible on stopping treatment. Since agranulocytosis can develop very rapidly, periodic leukocyte counts alone may not be effective in the early detection of these reactions.

During treatment with carbimazole:

1. The patient should be asked to immediately report signs and symptoms suggestive of infection, e.g. sore throat, fever, mouth ulcers.

2. A white cell count should be performed if there is any clinical evidence of infection.

3. The drug should be stopped promptly if there is clinical or laboratory evidence of neutropenia.

Carbimazole is an antithyroid agent which depresses the formation of thyroid hormone. Its main effect is to reduce the formation of iodotyrosines and hence of tri-iodothyronine and thyroxine. It is rapidly absorbed orally and almost completely excreted in the urine in 24 hours as the metabolite methimazole.